articleThe LancetMar 1, 2011Closed access

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

JCJavier CortésJOJoyce O’ShaughnessyDLDavid LoeschJLJoanne L. BlumLTLinda T. Vahdat

Vall d'Hebron Institute of Oncology · Vall d'Hebron Institut de Recerca · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,092
total citations
FWCI
30.94
Percentile
100%
References
35
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Eribulin
  • Medicine
  • Metastatic breast cancer
  • Internal medicine
  • Hazard ratio
  • Taxane
  • Breast cancer
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding